{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Dose+Escalation+of+Placebo&page=3",
    "query": {
      "intervention": "Dose Escalation of Placebo",
      "page": 3
    },
    "page_size": 10
  },
  "pagination": {
    "page": 3,
    "page_size": 10,
    "total_count": 990,
    "total_pages": 99,
    "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Dose+Escalation+of+Placebo&page=4&page_size=10",
    "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Dose+Escalation+of+Placebo&page=2&page_size=10"
  },
  "source": "remote",
  "last_synced_at": "2026-10-05T15:40:41.295Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT04620109",
      "title": "Clinical Evaluation of Safety and Tolerability of KDR2-2 Eye Drops in Healthy Volunteers With Pharmacokinetic Assessment",
      "overall_status": "UNKNOWN",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Corneal Neovascularization"
      ],
      "interventions": [
        {
          "name": "KDR2-2",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Guangzhou HuiBoRui Biological Pharmaceutical Technology Co. Ltd",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "55 Years",
        "sex": "ALL",
        "summary": "18 Years to 55 Years"
      },
      "enrollment_count": 62,
      "start_date": "2020-08-26",
      "completion_date": "2021-06-30",
      "has_results": false,
      "last_update_posted_date": "2020-11-06",
      "last_synced_at": "2026-10-05T15:40:41.295Z",
      "location_count": 1,
      "location_summary": "Glendale, California",
      "locations": [
        {
          "city": "Glendale",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04620109"
    },
    {
      "nct_id": "NCT02769065",
      "title": "Study of TAK-071 in Healthy Participants and Participants With Mild Cognitive Impairment/Mild Alzheimer Disease and Relative Bioavailability (BA) and Food Effect of TAK-071 in Healthy Participants",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Alzheimer Disease",
        "Healthy Volunteers"
      ],
      "interventions": [
        {
          "name": "TAK-071",
          "type": "DRUG"
        },
        {
          "name": "Donepezil",
          "type": "DRUG"
        },
        {
          "name": "TAK-071 Placebo",
          "type": "DRUG"
        },
        {
          "name": "Donepezil Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Takeda",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "90 Years",
        "sex": "ALL",
        "summary": "18 Years to 90 Years"
      },
      "enrollment_count": 179,
      "start_date": "2016-05-05",
      "completion_date": "2017-06-08",
      "has_results": true,
      "last_update_posted_date": "2019-06-10",
      "last_synced_at": "2026-10-05T15:40:41.295Z",
      "location_count": 1,
      "location_summary": "Glendale, California",
      "locations": [
        {
          "city": "Glendale",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02769065"
    },
    {
      "nct_id": "NCT06835296",
      "title": "A Study of Oral YUQ-A1007 in Healthy Volunteers",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Healthy"
      ],
      "interventions": [
        {
          "name": "YUQ-A1007 is a novel gut-enriched AhR agonist. This compound is undergoing preclinical development, and comprehensive nonclinical studies.",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Allianthera (Suzhou) Biopharmaceuticals Co., Ltd.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "65 Years",
        "sex": "ALL",
        "summary": "18 Years to 65 Years"
      },
      "enrollment_count": 47,
      "start_date": "2025-03-20",
      "completion_date": "2025-09-30",
      "has_results": false,
      "last_update_posted_date": "2025-12-26",
      "last_synced_at": "2026-10-05T15:40:41.295Z",
      "location_count": 1,
      "location_summary": "Anaheim, California",
      "locations": [
        {
          "city": "Anaheim",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT06835296"
    },
    {
      "nct_id": "NCT07731256",
      "title": "Semaglutide for Low Back Pain",
      "overall_status": "NOT_YET_RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Lower Back Pain",
        "Obesity (BMI>30)",
        "Chronic Lower Back Pain",
        "glp1 Agonist"
      ],
      "interventions": [
        {
          "name": "Semaglutide (administered by PDS290 pen-injector)",
          "type": "DRUG"
        },
        {
          "name": "Placebo (administered by PDS290 pen-injector)",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Washington University School of Medicine",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "85 Years",
        "sex": "ALL",
        "summary": "18 Years to 85 Years"
      },
      "enrollment_count": 250,
      "start_date": "2027-02-01",
      "completion_date": "2031-09-01",
      "has_results": false,
      "last_update_posted_date": "2026-07-28",
      "last_synced_at": "2026-10-05T15:40:41.295Z",
      "location_count": 2,
      "location_summary": "Birmingham, Alabama • St Louis, Missouri",
      "locations": [
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "St Louis",
          "state": "Missouri"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT07731256"
    },
    {
      "nct_id": "NCT01041222",
      "title": "Safety, Tolerability, and Activity Study of ISIS SOD1Rx to Treat Familial Amyotrophic Lateral Sclerosis (ALS) Caused by SOD1 Gene Mutations",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Familial Amyotrophic Lateral Sclerosis"
      ],
      "interventions": [
        {
          "name": "ISIS 333611",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Ionis Pharmaceuticals, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 33,
      "start_date": "2010-01",
      "completion_date": "2012-01",
      "has_results": false,
      "last_update_posted_date": "2012-04-13",
      "last_synced_at": "2026-10-05T15:40:41.295Z",
      "location_count": 4,
      "location_summary": "Baltimore, Maryland • Charlestown, Massachusetts • St Louis, Missouri + 1 more",
      "locations": [
        {
          "city": "Baltimore",
          "state": "Maryland"
        },
        {
          "city": "Charlestown",
          "state": "Massachusetts"
        },
        {
          "city": "St Louis",
          "state": "Missouri"
        },
        {
          "city": "Houston",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01041222"
    },
    {
      "nct_id": "NCT03542435",
      "title": "Randomized, Double-Blind, Placebo-Controlled, MAD Study to Assess the Safety, Tolerability, and Pharmacokinetics of SXC 2023",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Healthy Volunteers"
      ],
      "interventions": [
        {
          "name": "SXC-2023",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Promentis Pharmaceuticals, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "55 Years",
        "sex": "ALL",
        "summary": "18 Years to 55 Years"
      },
      "enrollment_count": 40,
      "start_date": "2018-04-26",
      "completion_date": "2018-09-10",
      "has_results": false,
      "last_update_posted_date": "2018-10-16",
      "last_synced_at": "2026-10-05T15:40:41.295Z",
      "location_count": 1,
      "location_summary": "Tempe, Arizona",
      "locations": [
        {
          "city": "Tempe",
          "state": "Arizona"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03542435"
    },
    {
      "nct_id": "NCT03437941",
      "title": "Study to Evaluate Exicorilant (CORT125281) in Combination With Enzalutamide in Patients With Metastatic Castration-Resistant Prostate Cancer",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1",
        "PHASE2"
      ],
      "conditions": [
        "Metastatic Castration-Resistant Prostate Cancer"
      ],
      "interventions": [
        {
          "name": "Exicorilant",
          "type": "DRUG"
        },
        {
          "name": "Enzalutamide",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Corcept Therapeutics",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "MALE",
        "summary": "18 Years and older · Male only"
      },
      "enrollment_count": 39,
      "start_date": "2018-02-20",
      "completion_date": "2023-01-12",
      "has_results": true,
      "last_update_posted_date": "2026-05-15",
      "last_synced_at": "2026-10-05T15:40:41.295Z",
      "location_count": 6,
      "location_summary": "Scottsdale, Arizona • Detroit, Michigan • Basking Ridge, New Jersey + 3 more",
      "locations": [
        {
          "city": "Scottsdale",
          "state": "Arizona"
        },
        {
          "city": "Detroit",
          "state": "Michigan"
        },
        {
          "city": "Basking Ridge",
          "state": "New Jersey"
        },
        {
          "city": "New York",
          "state": "New York"
        },
        {
          "city": "Portland",
          "state": "Oregon"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03437941"
    },
    {
      "nct_id": "NCT07654972",
      "title": "A Study of LY4174794 in Participants With Obesity or Overweight Who Are Otherwise Healthy",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Obesity",
        "Overweight"
      ],
      "interventions": [
        {
          "name": "LY4174794",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Eli Lilly and Company",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "65 Years",
        "sex": "ALL",
        "summary": "18 Years to 65 Years"
      },
      "enrollment_count": 108,
      "start_date": "2026-06-24",
      "completion_date": "2029-04",
      "has_results": false,
      "last_update_posted_date": "2026-09-01",
      "last_synced_at": "2026-10-05T15:40:41.295Z",
      "location_count": 2,
      "location_summary": "San Antonio, Texas • Salt Lake City, Utah",
      "locations": [
        {
          "city": "San Antonio",
          "state": "Texas"
        },
        {
          "city": "Salt Lake City",
          "state": "Utah"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT07654972"
    },
    {
      "nct_id": "NCT06024239",
      "title": "A Study to Evaluate the Pharmacokinetics, Safety, and Tolerability of ABBV-932 in Healthy Adult Participants, Participants With Generalized Anxiety Disorder (GAD) and Participants With Bipolar Disorder (BPD)",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Healthy Volunteers",
        "Generalized Anxiety Disorder (GAD)",
        "Bipolar Disorder (BPD)"
      ],
      "interventions": [
        {
          "name": "ABBV-932",
          "type": "DRUG"
        },
        {
          "name": "Placebo for ABBV-932",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "AbbVie",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "65 Years",
        "sex": "ALL",
        "summary": "18 Years to 65 Years"
      },
      "enrollment_count": 72,
      "start_date": "2023-08-31",
      "completion_date": "2025-03-04",
      "has_results": false,
      "last_update_posted_date": "2025-03-17",
      "last_synced_at": "2026-10-05T15:40:41.295Z",
      "location_count": 3,
      "location_summary": "Los Alamitos, California • Grayslake, Illinois • Marlton, New Jersey",
      "locations": [
        {
          "city": "Los Alamitos",
          "state": "California"
        },
        {
          "city": "Grayslake",
          "state": "Illinois"
        },
        {
          "city": "Marlton",
          "state": "New Jersey"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT06024239"
    },
    {
      "nct_id": "NCT00787059",
      "title": "AC6 Gene Transfer for CHF",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1",
        "PHASE2"
      ],
      "conditions": [
        "Congestive Heart Failure"
      ],
      "interventions": [
        {
          "name": "Ad5.hAC6",
          "type": "DRUG"
        },
        {
          "name": "Sucrose (3%)",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Hammond, H. Kirk, M.D.",
      "sponsor_class": "INDIV",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "80 Years",
        "sex": "ALL",
        "summary": "18 Years to 80 Years"
      },
      "enrollment_count": 56,
      "start_date": "2010-07",
      "completion_date": "2017-11-16",
      "has_results": false,
      "last_update_posted_date": "2018-02-09",
      "last_synced_at": "2026-10-05T15:40:41.295Z",
      "location_count": 7,
      "location_summary": "San Diego, California • Chicago, Illinois • Minneapolis, Minnesota + 3 more",
      "locations": [
        {
          "city": "San Diego",
          "state": "California"
        },
        {
          "city": "San Diego",
          "state": "California"
        },
        {
          "city": "Chicago",
          "state": "Illinois"
        },
        {
          "city": "Minneapolis",
          "state": "Minnesota"
        },
        {
          "city": "Salt Lake City",
          "state": "Utah"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00787059"
    }
  ]
}